News | March 23, 2026
Zydus launches affordable Semaglutide in India after patent expiry
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The initial consideration for the transaction is US$ 12 million
Subscribe To Our Newsletter & Stay Updated
